# Reversal of the Anti-platelet Effects of Ticagrelor

> **NCT02383771** · PHASE4 · COMPLETED · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 64 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Ticagrelor
- **DRUG:** Aspirin + Ticagrelor
- **DRUG:** Control
- **DRUG:** Aspirin + Ticagrelor

## Key facts

- **NCT ID:** NCT02383771
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2017-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02383771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02383771, "Reversal of the Anti-platelet Effects of Ticagrelor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02383771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*